Sign in →

Test Code GP210 GP210 Antibody, IgG, Serum


Additional Testing Requirements


This is a first line test when primary biliary cholangitis is strongly suspected. This test should be ordered in conjunction with AMA / Mitochondrial Antibodies (M2), Serum and SP100 / SP100 Antibody, IgG, Serum.



Specimen Required


Collection Container/Tube:

Preferred: Serum gel

Acceptable: Red top

Submission Container/Tube: Plastic vial

Specimen Volume: 0.5 mL

Collection Instructions: Centrifuge and aliquot serum into a plastic vial.


Secondary ID

620726

Useful For

Evaluating the risk of primary biliary cholangitis in anti-mitochondrial antibody (AMA)-negative patients by identification of gp210 antibodies

 

Estimating risk in AMA-positive patients with incomplete feature of disease

Method Name

Enzyme-Linked Immunosorbent Assay (ELISA)

Reporting Name

GP210 Antibody, IgG, S

Specimen Type

Serum

Specimen Minimum Volume

0.4 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Serum Refrigerated (preferred) 21 days
  Frozen  21 days

Reject Due To

Gross hemolysis OK
Gross lipemia OK
Gross icterus OK
Heat-treated specimens Reject

Reference Values

Negative: ≤20.0 Units

Equivocal: 20.1-24.9 Units

Positive: ≥25.0 Units

Day(s) Performed

Tuesday

Report Available

2 to 8 days

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

CPT Code Information

83516

LOINC Code Information

Test ID Test Order Name Order LOINC Value
GP210 GP210 Antibody, IgG, S 96560-8

 

Result ID Test Result Name Result LOINC Value
GP210 GP210 Antibody, IgG, S 96560-8

Forms

If not ordering electronically, complete, print, and send a Gastroenterology and Hepatology Test Request (T728) with the specimen.

Testing Algorithm

For more information see First-Line Screening for Autoimmune Liver Disease Algorithm.